Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin (RelapC)

This study has been terminated.
(Recruitment problems in Denmark and Norway)
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
Göteborg University
ClinicalTrials.gov Identifier:
NCT00641654
First received: March 17, 2008
Last updated: August 29, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2009
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)